These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1451727)

  • 1. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Gay C; Favereau JP; Gay R
    Eur J Clin Pharmacol; 1992; 43(4):435-6. PubMed ID: 1451727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Favereau JP; Gay R
    Int J Biomed Comput; 1994 Jun; 36(1-2):135-7. PubMed ID: 7927853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients.
    Gauthier T; Lacarelle B; Marre F; Villard PH; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):131-4. PubMed ID: 7927852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm.
    Debord J; Pessis C; Voultoury JC; Marquet P; Lotfi H; Merle L; Lachâtre G
    Fundam Clin Pharmacol; 1995; 9(1):57-61. PubMed ID: 7768489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation.
    Lacarelle B; Pisano P; Gauthier T; Villard PH; Guder F; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):127-30. PubMed ID: 7927851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin.
    Garraffo R; Iliadis A; Cano JP; Dellamonica P; Lapalus P
    J Pharm Sci; 1989 Sep; 78(9):753-7. PubMed ID: 2585270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
    Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
    Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of amikacin in critically ill patients.
    Bressolle F; Gouby A; Martinez JM; Joubert P; Saissi G; Guillaud R; Gomeni R
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1682-9. PubMed ID: 8807062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function.
    Lacarelle B; Granthil C; Manelli JC; Bruder N; Francois G; Cano JP
    Ther Drug Monit; 1987 Jun; 9(2):154-60. PubMed ID: 3617153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.
    Sultan E; Richard C; Pezzano M; Auzepy P; Singlas E
    Eur J Clin Pharmacol; 1988; 34(6):637-43. PubMed ID: 3169115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
    Chu XM; Rui JZ; Zhou YG; Dai YJ; Cai WM; Ling SS
    Yao Xue Xue Bao; 1996; 31(12):881-5. PubMed ID: 9863218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of amikacin in intensive care unit patients.
    Fernández de Gatta MM; Mendez ME; Romano S; Calvo MV; Dominguez-Gil A; Lanao JM
    J Clin Pharm Ther; 1996 Dec; 21(6):417-21. PubMed ID: 9201569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once- versus twice-daily administration of amikacin in pediatric patients with bronchopneumonia: plasma drug concentration and Bayesian pharmacokinetics estimation.
    el Desoky ES; Shoreit AH
    Ann Pharmacother; 1999 Jun; 33(6):749-50. PubMed ID: 10410192
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
    Debord J; Charmes JP; Marquet P; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):24-7. PubMed ID: 9021438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.